LABORATORY RESEARCH FGF-2 Disrupts Mitotic Stability in Prostate Cancer through the Intracellular Trafficking Protein CEP57 Scientists showed that FGF-2 rapidly uncouples centrosome duplication from the cell division cycle in prostate cancer cells through CEP57, an intracellular FGF-2 binding and trafficking factor. [Cancer Res] Abstract Androgen Receptor Degradation by the E3 Ligase CHIP Modulates Mitotic Arrest in Prostate Cancer Cells The authors report that low dose 2-methoxyestradiol, an endogenous estrogen metabolite, induces mitotic arrest in prostate cancer cells involving activation of the E3 ligase CHIP (C-terminus of Hsp70-interacting protein) and degradation of the androgen receptor. [Oncogene] Abstract Daxx Regulates Mitotic Progression and Prostate Cancer Predisposition Deregulation of APC/C is frequently observed in cancer cells and is suggested to contribute to chromosome instability and cancer predisposition. Here, researchers identified Daxx as a novel APC/C inhibitor frequently overexpressed in prostate cancer. [Carcinogenesis] Abstract Snake (Walterinnesia aegyptia) Venom-Loaded Silica Nanoparticles Induce Apoptosis and Growth Arrest in Human Prostate Cancer Cells Scientists recently demonstrated that venom extracted from Walterinnesia aegyptia (WEV) either alone or in combination with silica nanoparticles (WEV+NP) mediated the growth arrest and apoptosis of breast cancer cells. In the present study, they evaluated the impact of WEV alone and WEV+NP on the migration, invasion, proliferation and apoptosis of prostate cancer cells. [Apoptosis] Abstract | Full Article Prostaglandin E2 Induces Stromal Cell-Derived Factor-1 Expression in Prostate Stromal Cells by Activating Protein Kinase A and Transcription Factor Sp1 Recent reports indicate prostaglandin E2 (PGE2) can modulate tumor environment and promote angiogenesis through induction of stromal cell-derived factor 1 (SDF-1) production. The authors investigated the mechanism of PGE2-induced SDF-1 regulation in human prostate stromal cell and analyzed the effects in a stromal-epithelial interaction model. [Int J Biochem Cell Biol] Abstract Androgens Promote Prostate Cancer Cell Growth through Induction of Autophagy Scientists determined that androgens regulate overall cell metabolism and cell growth, in part, by increasing autophagy in prostate cancer cells. [Mol Endocrinol] Abstract Ursolic Acid Sensitizes Prostate Cancer Cells to TRAIL-Mediated Apoptosis Researchers investigated the sensitizing effects of ursolic acid, a pentacyclic triterpenoid found in many plants, on TRAIL-induced prostate cancer cell apoptosis. [Biochim Biophys Acta] Abstract Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes The authors investigated phenotypic changes associated with docetaxel-resistance in order to help determine the complexity of this problem and to assess the relevance of secreted exosomes in prostate cancer. [PLoS One] Full Article Insulin Receptor Isoforms A and B as well as Insulin Receptor Substrates-1 and -2 Are Differentially Expressed in Prostate Cancer In different cancers types, insulin receptor isoform composition or insulin receptor substrate (IRS) isoforms are different to healthy tissue. This may be a molecular link to increased cancer risk in diabetes and obesity. Since this is yet unclear for prostate cancer, the authors investigated IR isoform composition and IRS balance in prostate cancer compared to benign and tumor adjacent benign prostate tissue and brought this into relation to cell proliferation. [PLoS One] Full Article CLINICAL RESEARCH Long-Term Use of Angiotensin Receptor Blockers and the Risk of Cancer The authors aimed to determine whether angiotensin receptor blockers are associated with an overall increased risk of the four most common cancers, namely, lung, colorectal, breast and prostate cancers, and to explore these effects separately for each cancer type. [PLoS One] Full Article A Phase I Dose Escalation Trial of Vaccine Replicon Particles (VRP) Expressing Prostate-Specific Membrane Antigen (PSMA) in Subjects with Prostate Cancer In this first in human trial, two cohorts of three patients with castration resistant metastatic prostate cancer metastatic to bone were treated with up to five doses of either 0.9 × 107 IU or 0.36 × 108 IU of PSMA-VRP at weeks 1, 4, 7, 10 and 18, followed by an expansion cohort of six patients treated with 0.36 × 108 IU of PSMA-VRP at weeks 1, 4, 7, 10 and 18. [Vaccine] Abstract |